New shot combo aims to supercharge weight loss in obesity

NCT ID NCT06862791

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 35 times

Summary

This study tests whether combining two experimental weekly injections (AZD9550 and AZD6234) helps people with obesity or overweight who also have weight-related health problems lose more weight than placebo or either drug alone. About 377 adults aged 18-75 with a BMI of 27 or higher (plus a related condition) or 30 or higher are taking part. The main goal is to see how much weight is lost after 36 weeks of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Dothan, Alabama, 36305, United States
Research Site

Vestavia Hills, Alabama, 35216, United States
Research Site

Cerritos, California, 90703, United States
Research Site

Escondido, California, 92025, United States
Research Site

Huntington Park, California, 90255, United States
Research Site

Lincoln, California, 95648, United States
Research Site

Sacramento, California, 95864, United States
Research Site

Waterbury, Connecticut, 06708, United States
Research Site

Palm Harbor, Florida, 34684, United States
Research Site

Decatur, Georgia, 30030, United States
Research Site

Stockbridge, Georgia, 30281, United States
Research Site

Champaign, Illinois, 61822, United States
Research Site

South Bend, Indiana, 46617, United States
Research Site

Valparaiso, Indiana, 46383, United States
Research Site

Sioux City, Iowa, 51106, United States
Research Site

Southfield, Michigan, 48034, United States
Research Site

Missoula, Montana, 59804, United States
Research Site

Omaha, Nebraska, 68114, United States
Research Site

Albuquerque, New Mexico, 87107, United States
Research Site

Fargo, North Dakota, 58104, United States
Research Site

Cincinnati, Ohio, 45219, United States
Research Site

Columbus, Ohio, 43213, United States
Research Site

Tulsa, Oklahoma, 74133, United States
Research Site

Medford, Oregon, 97504, United States
Research Site

Kingsport, Tennessee, 37660, United States
Research Site

Brownsville, Texas, 78526, United States
Research Site

Houston, Texas, 77043, United States
Research Site

Arlington, Virginia, 22206, United States
Research Site

Renton, Washington, 98057, United States
Research Site

Maroochydore, 4556, Australia
Research Site

Maroubra, 2035, Australia
Research Site

Norwood, 5067, Australia
Research Site

St Albans, 3021, Australia
Research Site

St Leonards, 2065, Australia
Research Site

Calgary, Alberta, T2V 4J2, Canada
Research Site

Surrey, British Columbia, V3T 4G8, Canada
Research Site

Guelph, Ontario, N1G 0B4, Canada
Research Site

Hamilton, Ontario, L8J 0B6, Canada
Research Site

Hamilton, Ontario, L8L 5G8, Canada
Research Site

Sarnia, Ontario, N7T 4X3, Canada
Research Site

Stouffville, Ontario, L4A1H2, Canada
Research Site

Montreal, Quebec, H4N 2W2, Canada
Research Site

Berlin, 10787, Germany
Research Site

Essen, 45136, Germany
Research Site

Falkensee, 14612, Germany
Research Site

Hamburg, 22607, Germany
Research Site

Münster, 48145, Germany
Research Site

Oldenburg, 23758, Germany
Research Site

Chūōku, 103-0027, Japan
Research Site

Chūōku, 104-0031, Japan
Research Site

Fukuoka, 812-0025, Japan
Research Site

Shinjuku-ku, 160-0008, Japan
Research Site

Suita-shi, 565-0853, Japan

Conditions

Explore the condition pages connected to this study.

OBESITY OR OVERWEIGHT